Overview

A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Using Pirfenidone to treat Grade 2 or Grade3 radiation-induced lung injury, and observe the efficacy and safety of the drug.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Continent Pharmaceutical Co, Ltd.
Treatments:
Pirfenidone